Insight Molecular Diagnostics launches public offering of common stock, pre-funded warrants
IMDX•Insight Molecular Diagnostics launched an underwritten public offering of common stock or pre-funded warrants for certain investors. The underwriter will have a 30-day option to buy up to 15% additional shares, including shares underlying pre-funded warrants.
1. Offering details
Insight Molecular Diagnostics launched an underwritten public offering of common stock or pre-funded warrants for certain investors. The underwriter will have a 30-day option to buy up to 15% additional shares, including shares underlying pre-funded warrants. Net proceeds are intended for working capital and general corporate purposes, including transplantation research and development. Lake Street Capital Markets is the sole managing underwriter.




